Co-Diagnostics (NASDAQ:CODX) & Artiva Biotherapeutics (NASDAQ:ARTV) Head-To-Head Contrast

Artiva Biotherapeutics (NASDAQ:ARTV) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Insider & Institutional Ownership

15.0% of Co-Diagnostics shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Artiva Biotherapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 2.85, indicating that its stock price is 185% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Artiva Biotherapeutics and Co-Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1	0	4	1	2.83
Co-Diagnostics	1	1	1	1	2.50

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 420.69%. Co-Diagnostics has a consensus price target of $67.50, suggesting a potential upside of 5,769.57%. Given Co-Diagnostics’ higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Artiva Biotherapeutics.

Profitability

This table compares Artiva Biotherapeutics and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Valuation & Earnings

This table compares Artiva Biotherapeutics and Co-Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250,000.00	1,464.74	-$83.86 million	($3.30)	-2.27
Co-Diagnostics	$620,000.00	12.95	-$46.90 million	($10.32)	-0.11

Co-Diagnostics has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.